Priya Kumthekar, Caroline H Ko, Tatjana Paunesku, Karan Dixit, Adam M Sonabend, Orin Bloch, Matthew Tate, Margaret Schwartz, Laura Zuckerman, Ray Lezon, Rimas V Lukas, Borko Jovanovic, Kathleen McCortney, Howard Colman, Si Chen, Barry Lai, Olga Antipova, Junjing Deng, Luxi Li, Serena Tommasini-Ghelfi, Lisa A Hurley, Dusten Unruh, Nitya V Sharma, Manoj Kandpal, Fotini M Kouri, Ramana V Davuluri, Daniel J Brat, Miguel Muzzio, Mitchell Glass, Vinod Vijayakumar, Jeremy Heidel, Francis J Giles, Ann K Adams, C David James, Gayle E Woloschak, Craig Horbinski, Alexander H Stegh
Glioblastoma (GBM) is one of the most difficult cancers to effectively treat, in part because of the lack of precision therapies and limited therapeutic access to intracranial tumor sites due to the presence of the blood-brain and blood-tumor barriers. We have developed a precision medicine approach for GBM treatment that involves the use of brain-penetrant RNA interference-based spherical nucleic acids (SNAs), which consist of gold nanoparticle cores covalently conjugated with radially oriented and densely packed small interfering RNA (siRNA) oligonucleotides...
March 10, 2021: Science Translational Medicine